Follow
Natalia Kunst
Natalia Kunst
Centre for Health Economics, University of York
Verified email at york.ac.uk
Title
Cited by
Cited by
Year
Perspective and costing in cost-effectiveness analysis, 1974–2018
DD Kim, MC Silver, N Kunst, JT Cohen, DA Ollendorf, PJ Neumann
Pharmacoeconomics 38, 1135-1145, 2020
1642020
Calculating the expected value of sample information in practice: considerations from 3 case studies
A Heath, N Kunst, C Jackson, M Strong, F Alarid-Escudero, ...
Medical Decision Making 40 (3), 314-326, 2020
412020
Computing the expected value of sample information efficiently: practical guidance and recommendations for four model-based methods
N Kunst, ECF Wilson, D Glynn, F Alarid-Escudero, G Baio, A Brennan, ...
Value in Health 23 (6), 734-742, 2020
342020
A value of information analysis of research on the 21-gene assay for breast cancer management
NR Kunst, F Alarid-Escudero, AD Paltiel, SY Wang
Value in Health 22 (10), 1102-1110, 2019
212019
Estimating population-based recurrence rates of colorectal cancer over time in the United States
N Kunst, F Alarid-Escudero, E Aas, VMH Coupé, D Schrag, KM Kuntz
Cancer Epidemiology, Biomarkers & Prevention 29 (12), 2710-2718, 2020
192020
Use and costs of breast cancer screening for women in their 40s in a US population with private insurance
N Kunst, JB Long, X Xu, SH Busch, KA Kyanko, IB Richman, CP Gross
JAMA Internal Medicine 180 (5), 799-801, 2020
162020
Cost-effectiveness of neoadjuvant-adjuvant treatment strategies for women with erbb2 (her2)–positive breast cancer
N Kunst, SY Wang, A Hood, SS Mougalian, MP DiGiovanna, K Adelson, ...
JAMA network open 3 (11), e2027074-e2027074, 2020
152020
Simulating study data to support expected value of sample information calculations: a tutorial
A Heath, M Strong, D Glynn, N Kunst, NJ Welton, JD Goldhaber-Fiebert
Medical Decision Making 42 (2), 143-155, 2022
122022
Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia
G Goshua, P Sinha, N Kunst, L Pischel, AI Lee, A Cuker
American journal of hematology 98 (1), 122-130, 2023
102023
Cost-effectiveness of nivolumab plus ipilimumab with and without chemotherapy for advanced non-small cell lung cancer
SC Yang, N Kunst, CP Gross, JD Wang, WC Su, SY Wang
Frontiers in oncology 11, 760686, 2021
92021
Emerging therapies for COVID-19: the value of information from more clinical trials
SW Dijk, EM Krijkamp, N Kunst, CP Gross, JB Wong, MGM Hunink
Value in Health 25 (8), 1268-1280, 2022
82022
Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research
N Kunst, NK Stout, G O’Brien, KD Christensen, PM McMahon, AC Wu, ...
JNCI: Journal of the National Cancer Institute 114 (5), 722-731, 2022
82022
A review of web-based tools for value-of-information analysis
H Tuffaha, C Rothery, N Kunst, C Jackson, M Strong, S Birch
Applied health economics and health policy 19, 645-651, 2021
72021
Collaborative Network for Value of Information. Computing the expected value of sample information efficiently: practical guidance and recommendations for four model-based methods
N Kunst, ECF Wilson, D Glynn, F Alarid-Escudero, G Baio, A Brennan, ...
Value Health 23 (6), 734-742, 2020
62020
A guide to an iterative approach to model-based decision making in health and medicine: an iterative decision-making framework
N Kunst, EA Burger, VMH Coupé, KM Kuntz, E Aas
PharmacoEconomics 42 (4), 363-371, 2024
52024
Consolidated Health Economic Evaluation Reporting Standards-Value of Information (CHEERS-VOI): Explanation and Elaboration
N Kunst, A Siu, M Drummond, SE Grimm, J Grutters, D Husereau, ...
Value in Health 26 (10), 1461-1473, 2023
52023
Treatment sequencing patterns and associated direct medical costs of metastatic breast cancer care in the United States, 2011 to 2021
RJ Chehayeb, A Hood, X Wang, R Miksad, SS Mougalian, MB Lustberg, ...
JAMA network open 5 (11), e2244204-e2244204, 2022
52022
Accounting for household transmission dynamics in realistic epidemic models
F Alarid-Escudero, A Luviano, N Kunst, Y Peralta, JD Goldhaber-Fiebert
42nd Annual Meeting of the Society for Medical Decision Making, 2020
52020
Computing the expected value of sample information efficiently: expertise and skills required for four model-based methods
NR Kunst, E Wilson, F Alarid-Escudero, G Baio, A Brennan, M Fairley, ...
arXiv preprint arXiv:1910.03368, 2019
52019
CHEERS value of information (CHEERS-VOI) reporting standards–explanation and elaboration
N Kunst, A Siu, M Drummond, S Grimm, J Grutters, D Husereau, ...
Value in Health, 2023
42023
The system can't perform the operation now. Try again later.
Articles 1–20